Wednesday, 5 August 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 05 August 2026
News

Deal paves way for global rollout

Posted 4 August 2026 PM

Pharmanovia has inked a deal worth up to $601.9 million with Chinese biotech IMPACT Therapeutics to commercialise senaparib in 66 countries, including Australia.

The highly potent PARP1/2 inhibitor developed by the Shanghai headquartered biotech is currently on approved in China, where it also reimbursed via the National Reimbursed Drug List as a first-line maintenance therapy for adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer achieving complete or partial response to platinum-based chemotherapy.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (21)

Access & Reimbursement (2)

Clinical & Medical, R&D (11)

Regulatory, Pharmacovigilance & QA (3)

Devices (1)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.